Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

The clinical trial failure dilemma. What constitutes clinical trial failure is a matter of perspective. For sponsors, the ...

In this video interview, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, talks collaboration and maximizing resources among the various stakeholders in ...

In this video interview, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, discusses the most prominent challenges he is seeing in the space right now ...

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible ...

As oncology research centers scale eSource adoption, the field is shifting toward a fully digital, clinical trial ecosystem.

These were across five common KRIs (adverse events, serious adverse events, screen failure, early termination, and data entry ...

Since the Orphan Drug Act went into effect in 1983, more than 600 drugs have been approved for rare diseases, according to ...

Many clinical researchers lament the rise of misinformation and yearn for the orderly days of fewer, more authoritative ...

Examining the implications of the recent US executive orders concerning diversity, equity, and inclusion pursuits—and the key questions each clinical trial stakeholder must now navigate.

In this video interview, Thierry Escudier, portfolio lead, Pistoia Alliance, talks the current landscape of sustainability in clinical trials and how stakeholders are beginning to pay more attention ...

In this video interview, Thierry Escudier, portfolio lead, Pistoia Alliance, highlights the need for maintaining data privacy in a highly regulated clinical research industry.